Around June 17, 2026, OpenAI disclosed a case in which its general-purpose large language model GPT-5.4 improved a synthesis reaction used in drug discovery, turning an AI-generated idea into a result validated by experiment. The model supported the workflow from literature review to hypothesis generation, experimental design and data analysis, and concrete yield gains were confirmed through a robotic synthesis platform working with a specialized lab.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.